Canada Markets close in 6 hrs 25 mins

Perimeter Medical Imaging AI, Inc. (PYNKF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.4600+0.0505 (+3.58%)
As of 03:52PM EDT. Market open.
Sign in to post a message.
  • T
    Tt
    So happy I got out at 5 … this things a dog
  • J
    John
    omg ..13 shares sold...
  • J
    John
    OMG..800 SHARES SOLD..!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
  • J
    John
    something big happening ? ..look at that volume...lolol
  • J
    John
    see you in 10 years..lol
  • P
    Patrick
    Insider buying yesterday
  • R
    Richard
    Chamath has entered the chat
  • A
    Agni
    Yahoo is being a pain not letting me post links. I have written a new research report on Perimeter Medical on my substack found at the following URL. Please subscribe to my substack and read my report:
    b
    i
    t
    .
    l
    y
    /perimetermed
  • X
    Xero
    The last time PINK went to LD Micro event in December 2020, the share price moved from 2.2$ to 3.99$ in a two month span.
  • X
    Xero
    Hold the line till March 8th to participate in the next run.
  • X
    Xero
    This company has solid business model and is indeed addressing an unmet need. I expected a huge take off in March as they will start rolling out their devices to the buyers. This early surprise is such a welcome. Cheers everyone!
  • R
    Robot Man
    any rumors of a buyout?
  • X
    Xero
    Some short selling is taking place on this stock today. You might do yourself a favor by buying the dips and holding until the Friday!
  • X
    Xero
    Congratulations everyone..well deserved
  • S
    Sandy
    Perimeter Medical AI - Pitch 1/2 - CEO Jeremy Sobotta - Looking to the Edge of Cancer: https://www.youtube.com/watch?v=5meTUPcqQVs&ab_channel=RadiusResearch
    Perimeter Medical AI - Pitch 1/2 - CEO Jeremy Sobotta - Looking to the Edge of Cancer
    www.youtube.com
  • S
    Sidney
    I just watched the company's presentation from the LD Micro conference on 12/14/20. This is what I noted:
    1. AI study - part 1 (400 patients) data collection should end in Q1 2021. Part 2 - endpoint will be reduction in re-operation rate of 50% noted. 600 patients at 10 sites.
    2. No competition - MarginProbe by Dillon Tech is the closest, but it only gives a yes/no answer without further details and very poor specificity of 46% (54% false positives). KOL's don't consider this viable competition.
    3. Cash position - $9M in cash + can draw upon the $7.4M grant from CPRIT, which gives a 3 year runway. This was my biggest concern. So the company won't have to worry about cash until the end of 2023. That's with no revenue coming in.
    4. Device obtained FDA cleared via 510(k) pathway in March 2019. Sales effort should ramp up Q1 of this year
    5. Insiders own 45% of the company. Roadmap capital owns 40% (shares locked up for 18 months from June 2020) and Management owns 5%.
  • X
    Xero
    Short-term turbulence due to expiring warrants..Hold the line folks.. This company is solid and ready to shake the markets in the next 2-3 months.
  • K
    Kyle
    How is nobody really talking about this stock?
  • J
    Jj
    Looking like this is flat? I thought the Bloomberg coverage would have helped. Anything thoughts ?
  • X
    Xero
    Just finished watching the replay of our company's presentation at LD Micro. The best takeaway for me is that the CEO is now positioning the company as the one solving/simplifying the problems with "cancer surgeries", instead of only "breast cancer surgeries". I must say I have been waiting for this change in outlook for a while. A full realization of the product's capabilities!!!! This is great!